Mesoblast Ltd MESO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:32 PM EDT
7.09quote price arrow down-0.01 (-0.14%)
Volume
2,911
Close
7.10quote price arrow up+0.86 (+13.78%)
Volume
664,010
52 week range
1.61 - 10.24
Loading...
  • Open7.00
  • Day High7.60
  • Day Low6.82
  • Prev Close6.24
  • 52 Week High10.24
  • 52 Week High Date07/17/23
  • 52 Week Low1.61
  • 52 Week Low Date01/18/24

Key Stats

  • Market Cap810.667M
  • Shares Out114.18M
  • 10 Day Average Volume0.34M
  • Dividend-
  • Dividend Yield-
  • Beta3.52
  • YTD % Change222.73

KEY STATS

  • Open7.00
  • Day High7.60
  • Day Low6.82
  • Prev Close6.24
  • 52 Week High10.24
  • 52 Week High Date07/17/23
  • 52 Week Low1.61
  • 52 Week Low Date01/18/24
  • Market Cap810.667M
  • Shares Out114.18M
  • 10 Day Average Volume0.34M
  • Dividend-
  • Dividend Yield-
  • Beta3.52
  • YTD % Change222.73

RATIOS/PROFITABILITY

  • EPS (TTM)-0.92
  • P/E (TTM)-7.76
  • Fwd P/E (NTM)-5.07
  • EBITDA (TTM)-50.981M
  • ROE (TTM)-14.49%
  • Revenue (TTM)7.466M
  • Gross Margin (TTM)-190.91%
  • Net Margin (TTM)-978.54%
  • Debt To Equity (MRQ)23.98%

EVENTS

  • Earnings Date05/28/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mesoblast Ltd

 

Profile

MORE
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic...
William Burns
Non-Executive Independent Vice Chairman of the Board
Jane Bell
Non-Executive Independent Chairman of the Board
Silviu Itescu
Chief Executive Officer, Executive Director
Dagmar Rosa-Bjorkeson
Chief Operating Officer
Andrew Chaponnel
Interim Chief Financial Officer
Peter Howard
General Counsel, Corporate Executive
Address
L 38 55 Collins St
Melbourne, VIC
3000
Australia

Top Peers

SYMBOLLASTCHG%CHG
GBIO
Generation Bio Co
2.85-0.05-1.72%
PRQR
ProQR Therapeutics NV
1.97+0.03+1.55%
INO
Inovio Pharmaceuticals Inc
11.50+0.93+8.80%
DRTS
Alpha Tau Medical Ltd
2.42+0.02+0.62%
OBIO
Orchestra Biomed Holdings Inc
4.39UNCHUNCH